3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
9
Lymphoid
4
CNS
4
Myeloid
2
Gynecologic
2
Sarcoma
1
Plasma cell
1
Gastrointestinal
1
Breast
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Osteosarcoma
1
Neuroblastoma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Interventions
Radiotherapy
216
Cyclophosphamide
211
Doxorubicin
207
Temozolomide
181
Ifosfamide
121
Filgrastim
111
Etoposide
101
Imatinib Mesylate
99
Vincristine
92
Gemcitabine
89
Bevacizumab
83
Magnetic Resonance Spectroscopy
79
Irinotecan
79
pembrolizumab
75
Radiation
67
Carboplatin
65
pazopanib
60
Methotrexate
60
Nivolumab
58
Cisplatin
58
fludarabine phosphate
56
Peripheral Blood Stem Cell Transplantation
56
Specimen Handling
53
Docetaxel
50
Busulfan
48
Trabectedin
47
Biopsy
47
Melphalan
46
Surgical Procedures, Operative
45
Paclitaxel
44
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
IL32 protein, human
×
Sarcoma
×
Clear all
NCT02100891
2025-03-19
STIR
Medical College of Wisconsin
Phase 2
Terminated
15 enrolled
11 charts